T
Thomas M. Grogan
Researcher at Ventana Medical Systems
Publications - 239
Citations - 27073
Thomas M. Grogan is an academic researcher from Ventana Medical Systems. The author has contributed to research in topics: Lymphoma & Diffuse large B-cell lymphoma. The author has an hindex of 70, co-authored 239 publications receiving 26178 citations. Previous affiliations of Thomas M. Grogan include University of Arizona & Hoffmann-La Roche.
Papers
More filters
Journal ArticleDOI
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
Andreas Rosenwald,George E. Wright,Wing C. Chan,Wing C. Chan,Joseph M. Connors,Elias Campo,Richard I. Fisher,Randy D. Gascoyne,H. Konrad Muller-Hermelink,Erlend B. Smeland,Jena M. Giltnane,Elaine M. Hurt,Hong Zhao,Lauren Averett,Liming Yang,Wyndham H. Wilson,Elaine S. Jaffe,Richard M. Simon,Richard D. Klausner,John Powell,P L Duffey,Dan L. Longo,Timothy C. Greiner,Dennis D. Weisenburger,Warren G. Sanger,Bhavana J. Dave,James C. Lynch,Julie M. Vose,James O. Armitage,Emilio Montserrat,Armando López-Guillermo,Thomas M. Grogan,Thomas P. Miller,Michel Leblanc,German Ott,Stein Kvaløy,Jan Delabie,Harald Holte,Peter Krajci,Trond Stokke,Louis M. Staudt +40 more
TL;DR: DNA microarrays can be used to formulate a molecular predictor of survival after chemotherapy for diffuse large-B-cell lymphoma and this gene-based predictor and the international prognostic index were independent prognostic indicators.
Journal ArticleDOI
Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's Lymphoma
Richard I. Fisher,Ellen R. Gaynor,Steve Dahlberg,Martin M. Oken,Thomas M. Grogan,Evonne M. Mize,John H. Glick,Charles A. Coltman,Thomas P. Miller +8 more
TL;DR: CHOP remains the best available treatment for patients with advanced-stage intermediate-grade or high-grade non-Hodgkin's lymphoma.
Journal ArticleDOI
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells
Sandeep S. Dave,George E. Wright,Bruce K. Tan,Andreas Rosenwald,Andreas Rosenwald,Randy D. Gascoyne,Wing C. Chan,Richard I. Fisher,Rita M. Braziel,Lisa M. Rimsza,Thomas M. Grogan,Thomas P. Miller,Michael LeBlanc,Timothy C. Greiner,Dennis D. Weisenburger,James C. Lynch,Julie M. Vose,James O. Armitage,Erlend B. Smeland,Stein Kvaløy,Harald Holte,Jan Delabie,Joseph M. Connors,Peter M. Lansdorp,Qin Ouyang,T. Andrew Lister,Andrew Davies,Andrew J. Norton,H. Konrad Muller-Hermelink,German Ott,Elias Campo,Emilio Montserrat,Wyndham H. Wilson,Elaine S. Jaffe,Richard M. Simon,Liming Yang,John Powell,Hong Zhao,Neta Goldschmidt,Michael Chiorazzi,Louis M. Staudt +40 more
TL;DR: The length of survival among patients with follicular lymphoma correlates with the molecular features of nonmalignant immune cells present in the tumor at diagnosis.
Journal ArticleDOI
Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma
Andreas Rosenwald,George E. Wright,Karen Leroy,Xin-You Yu,Philippe Gaulard,Randy D. Gascoyne,Wing C. Chan,Tong Zhao,Corinne Haioun,Timothy C. Greiner,Dennis D. Weisenburger,James C. Lynch,Julie M. Vose,James O. Armitage,Erlend B. Smeland,Stein Kvaløy,Harald Holte,Jan Delabie,Elias Campo,Emili Montserrat,Armando López-Guillermo,German Ott,H. Konrad Muller-Hermelink,Joseph M. Connors,Rita M. Braziel,Thomas M. Grogan,Thomas M. Grogan,Richard I. Fisher,Richard I. Fisher,Thomas P. Miller,Thomas P. Miller,Michael LeBlanc,Michael LeBlanc,Michael Chiorazzi,Hong-Bo Zhao,Liming Yang,John Powell,Wyndham H. Wilson,Elaine S. Jaffe,Richard Simon,Richard D. Klausner,Louis M. Staudt +41 more
TL;DR: Gene expression profiling strongly supported a relationship between PMBL and Hodgkin lymphoma: over one third of the genes that were more highly expressed in PMBL than in other DLBCLs were also characteristically expressed in Hodgkinymphoma cells.
Journal ArticleDOI
Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma
Thomas P. Miller,Steve Dahlberg,J. Robert Cassady,David J. Adelstein,Catherine M. Spier,Thomas M. Grogan,Michael LeBlanc,Susan Carlin,Ellen M. Chase,Richard I. Fisher +9 more
TL;DR: Three cycles of CHOP followed by involved-field radiotherapy are superior to eight cycles ofCHOP alone for the treatment of localized intermediate- and high-grade non-Hodgkin's lymphoma.